GlassScriptPhysician profile
Alejandro Albert Verdugo
NPI 1679885297
$9,702.31
in general payments reported to CMS, 2019-2025
33 companies · $4,798 in 2025
The $4,798 reported for 2025 was more than what 90% of Hand Surgery providers received nationally (typical 2025 total: $270).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $133 · 2020: $2,495 · 2021: $314 · 2022: $378 · 2023: $1,332 · 2024: $252 · 2025: $4,798.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $4,054 · Food and Beverage: $2,328.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $4,054.15 |
| Food and Beverage | $2,328.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $4,711.03 | 2019-2025 | Q-Fix, Bioinductive Implant With Arthroscopic Delivery System - Medium, Mini-Open Latarjet |
| Axogen | $2,014.36 | 2019-2025 | Avance Nerve Graft |
| Anika Therapeutics, INC. | $822.78 | 2023 | Hemicap Wrist, Integrity Implant, Tactoset |
| Pacira Therapeutics, INC. | $296.55 | 2019-2021 | |
| Zimmer Biomet Holdings, INC. | $285.39 | 2023-2025 | Comprehensive Shoulder System, Allogenix |
| Stryker Corporation | $148.42 | 2021-2023 | Alphavent, Cinchlock |
| Arthrex, INC. | $141.88 | 2022 | |
| Linvatec Corporation | $138.62 | 2020 | |
| Ferring Pharmaceuticals INC. | $111.51 | 2019-2025 | Euflexxa |
| Horizon Therapeutics Plc | $109.92 | 2019-2021 | |
| Depuy Synthes Sales INC. | $96.44 | 2024-2025 | Monovisc |
| Pacira Pharmaceuticals Incorporated | $93.21 | 2022-2025 | Iovera, Zilretta |
| Baudax Bio INC. | $71.69 | 2021-2022 | |
| Boston Scientific Corporation | $60.08 | 2021 | |
| Baxter Healthcare | $56.90 | 2022-2025 | Floseal |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orthofix Medical, INC. | $51.96 | 2024-2025 | Physio-Stim |
| Abbvie INC. | $48.02 | 2022 | |
| Rattan and Associates | $46.33 | 2022-2023 | |
| Bioventus LLC | $44.55 | 2025 | Durolane, Xcell |
| Tactile Systems Technology INC | $42.35 | 2021-2022 | |
| Globus Medical, INC. | $34.76 | 2025 | Senza |
| Solventum Corporation | $33.46 | 2025 | Activ.A.C. |
| Amgen INC. | $32.07 | 2021-2023 | Evenity, Prolia |
| Kowa Pharmaceuticals America, INC. | $31.25 | 2022-2023 | Seglentis |
| Merck Sharp & Dohme LLC | $29.40 | 2024-2025 | Bridion |
| Heron Therapeutics, INC. | $28.31 | 2021 | |
| Nalu Medical, INC. | $22.47 | 2023 | Nalu Neurostimulation System |
| Illuminoss Medical, INC. | $22.06 | 2019 | |
| Endo USA, INC. | $19.85 | 2025 | Xiaflex |
| Kerecis Limited | $18.05 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Ossur Americas, INC. | $14.24 | 2024 | I-Digits Quantum |
| Advanced Oxygen Therapy INC. | $12.71 | 2025 | Topical Oxygen Chamber For Extremities |
| Avanos Medical | $11.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandro Verdugo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.